Abbott and DexCom are leading players in the continuous glucose monitoring market, valued at 13.4 billion dollars in 2025. Abbott's FreeStyle Libre CGM sales reached 2 billion dollars in the first quarter of 2026, up 7.5 percent year over year, though growth was affected by an international tender delay and a tough prior-year comparison. DexCom is benefiting from broader CGM access, new product launches like the G7 15 Day sensor, and expanded insurance coverage, with more than one million users connected to automated insulin delivery systems worldwide. Year to date, Abbott shares have declined 25.6 percent while DexCom shares have climbed 4.1 percent. Abbott trades at a forward price-to-sales ratio of 2.99 times, below its median of 4.63 times, while DexCom's ratio is 4.88 times, also below its median of 9.93 times. DexCom carries a Zacks Rank of 3, or Hold, while Abbott has a Zacks Rank of 4, or Sell.
Abbott LaboratoriesAbbott's FreeStyle Libre CGM sales growth slowed to 7.5% due to an international tender delay and tough prior-year comparison.
DexCom IncDexCom benefits from broader CGM access, new product launches like G7 15 Day sensor, and expanded insurance coverage.